Pharmacogenetic aspects of biological variability

Journal of Gastroenterology and Hepatology

Volumn 3, Issue 6, 1988, Pages 623-633

  KUPFER A ^a   ZEUGIN, T ^a   PREISIG, R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOPHENAZONE; AMOBARBITAL; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARBOCISTEINE; DEBRISOQUINE; DIHYDRALAZINE; FLUOROURACIL; ISONIAZID; MEPHENYTOIN; NIFEDIPINE; PROCAINAMIDE; SALAZOSULFAPYRIDINE; SULFADIMIDINE; SULFONAMIDE; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; URACIL;

ADVERSE DRUG REACTION; BIOTRANSFORMATION; DRUG ELIMINATION; DRUG INTERACTION; HUMAN; PHARMACOGENETICS; PHENOTYPE; REVIEW;

EID: 0024240138     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1988.tb00793.x     Document Type: Article

References (64)

1. Enzymatic deficiency in primaquine‐sensitive erythrocytes
2. Genetic factors related to glaucoma
3. Commentary: Malignant hyperthermia
4. Special modifications of the fluorescent screening method for glucose‐6‐phosphate dehydrogenase deficiency
5. First premarital screening of thalassaemia carriers in intermediate schools in Latium
6. A highly cost effective method of mass screening for thalassaemia
7. Molecular analysis of human disease: dissection of β‐thalassemia
8. On the identification and frequency of the J and K cholinesterase phenotypes in a Caucasian population
9. Pseudocholinesterase‐variants in Germany and Czechoslovakia
10. A method for the detection of atypical forms of human serum cholinesterase: determination of dibucaine numbers
11. Drug‐induction of the acute porphyrias
12. The porphyrias
13. Polymorphic hydroxylation of debrisoquine in man
14. Pharmacogenetics of tolbutamide metabolism in humans
15. Genetic aspects of the polymodally distributed sulphoxidation of S‐carboxymethyl‐L‐cysteine in man
16. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man
17. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man
18. Genetic determinants of alcohol and aldehyde dehydrogenases and alcohol metabolism
19. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases and their relationship to alcohol metabolism and alcoholism
20. Disease and acetylation polymorphism
21. Hyperbilirubinemia
22. A method for studying drug metabolism in populations: Racial differences in amobarbital metabolism
23. Familial pyrmidinemia and pyrimidinuria associated with severe fluorouracil toxicity
24. Deficiency of mephenytoin hydroxylation in a Caucasian population: frequency of a new oxidative drug metabolism polymorphism
25. High plasma concentrations of β‐receptor blocking drugs and deficient debrisoquine hydroxylation
26. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine
27. Beta‐blockers and drug oxidation status
28. The pharmacokinetics of indoramin and 6‐hydroxyin‐doramin in poor and extensive hydroxylators of debrisoquine
29. Role of oxidation polymorphism on blood concentrations of amitriptyline and its metabolites in man
30. E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation
31. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications
32. The debrisoquine hydroxylation test predicts steady‐state plasma levels of desipramine
33. Importance of oxidative polymorphism and levomepromazine treatment on the steady‐state blood concentrations of clomipramine and its major metabolites
34. Polymorphism of carbon oxidation of drugs and clinical implications
35. Inhibition of debrisoquine metabolism by propafenone in man
36. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
37. Pharmacokinetics of N‐propylajmaline in relation to polymorphic sparteine oxidation
38. Defective N‐oxidation of sparteine in man: a new pharmacogenetic defect
39. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta‐adrenoceptor blocking agents
40. Polymorphic dextromethorphan metabolism: cosegregation of oxidative O‐demethylation with debrisoquine hydroxylation
41. Stereoselective mephobarbital hydroxylation cosegregation with mephenytoin hydroxylation
42. Family studies of mephenytoin hydroxylation deficiency
43. Chromosomal assignment of human cytochrome P‐450 (debrisoquine/sparteine type) to chromosome 22
44. Liver damage associated with perhexiline maleate
45. Perhexiline‐induced lipidasis in the dark Agouti (DA) rat
46. Perhexiline maleate‐induced cirrhosis
47. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations
48. Sparteine oxidation is practically abolished in quinidine‐treated patients
49. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo
50. Single‐dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
51. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine
52. Accumulation of acetaldehyde in alcohol‐sensitive Japanese: relation to ethanol and acetaldehyde oxidizing capacity
53. Application of a high performance liquid chromatography method for screening of aldehyde dehydrogenase isozyme deficiency in hair roots from different ethnic groups
54. The acetylation of sulfamethazine and sulfamethoxypyridazine by human subjects
55. An improved and simplified method of detecting the acetylator phenotype
56. Polymorphic N‐acetylation of a caffeine metabolite
57. Genetic control of isoniazid metabolism in man
58. Hydralazine‐induced systemic lupus erythematosus: influence of HLA‐DR and sex on susceptibility
59. Aldehyde dehydrogenase deficiency as cause of facial flushing reaction to alcohol in Japanese
60. Possible protective role against alcoholism for aldehyde dehydrogenase isozyme deficiency in Japan
61. Ecogenetics of Parkinson's disease: 4‐hydroxylation of debrisoquine
62. The association of the slow acetylator phenotype with bladder cancer
63. The rate of isoniazid inactivation in Finnish diabetic and non‐diabetic patients